Diabetes mellitus is a metabolic disorder characterized by the presence of hyperglycemia due to defective insulin secretion, insulin action or both.  There is an unmet medical need for people with Type 2 Diabetes for products with the potential to improve clinical outcomes through reduced treatment burden, such as fewer injections and increased treatment adherence compared to other treatment regimens requiring daily or several weekly injections.

This study will compare the new investigational medicine IcoSema, which is a combination of

insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week.  The

study will look at how well IcoSema controls blood sugar level when compared to insulin icodec. 

The study will last a little over one year. 

A few qualifications to participate are: 

• Male or female above or equal to 18 years of age 
• Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening 
• Treated with once-daily or twice-daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20-80 units/day ≥ 90 days before screening

The prevalence of obesity has been increasing during the last 30 years and globally, more than 650 million people have obesity.  Obesity is associated with an increased risk of developing type 2 diabetes (T2D), dyslipidemia, hypertension, cardiovascular (CV) disease, obstructive sleep apnea, Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NAFLD/NASH), urinary incontinence, several types of cancers, and increased mortality. In addition, individuals with obesity experience reduced health-related quality of life including reduced physical function.  Several associations, organizations and individual countries have recognized that obesity should be treated as a chronic disease.

This research study will test the investigational medicine for safety and effectiveness (helping people lose weight) when compared to a medication already approved or to placebo (no active ingredients).

Qualified participants will:

• See a physician at no cost
• Receive medication for obesity
• Routine meetings with a registered Dietician
• Receive compensation for time and travel  

There is an unmet medical need to improve the treatment of patients with established atherosclerotic cardiovascular disease (ASCVD), especially those with chronic kidney disease (CKD), and thereby reduce their risk of cardiovascular (CV) events.  Inflammation is an additional important risk factor to address in patients with ASCVD at high risk of major adverse cardiovascular events (MACE).

The primary objective of this study is to demonstrate the superiority of the study drug given once monthly in reducing the risk of major adverse cardiovascular events when compared to placebo, both added to standard of care, in participants with established ASCVD, CKD and systemic inflammation.  Standard of care treatment will be maintained throughout the study for all participants.

Qualified participants will:

• See a physician at no cost
• Receive pertinent tests and imaging at no cost
• Receive compensation for time and travel  

People with COPD are commonly treated with drugs delivered by a metered-dose inhaler (MDI).  An MDI is a device that delivers a set amount of medication to the lungs in a short burst of gas upon inhalation. This study wants to find out if the propellant (liquid compressed gas) called hydrofluoroolefin (HFO), which helps deliver the drug from the inhaler, is as safe and easy to tolerate by your body, as the currently used liquid gas called hydrofluoroalkane (HFA).   

HFO is being tested because it has a near-zero Global Warming Potential (GWP) and is more friendly to the environment than the currently used HFA due to being less harmful to the atmosphere.

 This study will last from 12-52 weeks. 

A few qualifications to participate are: 

• Participants must be 40 to 80 years of age inclusive 
• Participants who have a documented history of diagnosed COPD 
• Participants who have been regularly using dual ICS/LABA, LAMA/LABA, or ICS/LAMA/LABA (open or fixed-dose combinations) inhaled maintenance therapies for the management of their COPD for at least 6 weeks prior to Screening

People with Type 2 diabetes (T2D) often have multiple unmet medical needs related to cardiovascular risks, including hypertension and dyslipidaemia. It has been consistently demonstrated that weight loss in participants with T2D has a beneficial impact not only on glycaemic control, but also on other cardiovascular risk markers.  The risk of obesity-related complications increases with increasing BMI, and weight loss can have significant health benefits in terms of slowing the progression of T2D. 

This study will look at how the investigational dose of semaglutide works in helping people with excess body weight and type 2 diabetes lose weight and better control blood sugar levels. This will be compared to a placebo (no active ingredient) and a lower dose of semaglutide. 

This study will last about 1 ½ years. 

A few qualifications to participate are: 

• Male or female above or equal to 18 years of age
• Diagnosed with T2D greater than or equal to 180 days prior to screening
• History of at least one self-reported unsuccessful dietary effort to lose body weight
• Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs